tiprankstipranks
Trending News
More News >
Ekso Bionics Holding (EKSO)
:EKSO

EKSO BIONICS (EKSO) AI Stock Analysis

Compare
621 Followers

Top Page

EK

EKSO BIONICS

(NASDAQ:EKSO)

Rating:46Neutral
Price Target:
$3.50
▲(1.16%Upside)
EKSO BIONICS faces significant financial and operational challenges, reflected in weak financial performance and negative technical indicators. While there are positive signs from strategic partnerships and cash position improvements, the overall outlook remains cautious due to declining revenue and macroeconomic uncertainties impacting the enterprise health segment.
Positive Factors
Distribution Network Expansion
Ekso continues to expand its distribution network for the Ekso Indego Personal product.
Revenue Growth Outlook
Revenue growth is expected in both the legacy enterprise business and Indego Personal, indicating a positive outlook for 2025.
Strategic Partnerships
Strategic partnerships have been formed to broaden access to Ekso Indego Personal and navigate the reimbursement process, potentially expanding the market and driving long-term value for Ekso.
Negative Factors
Enterprise Revenue Challenges
Softer enterprise revenue due to customer budget cuts.
Medicare Reimbursement Complexity
Numerous activities must take place before a Medicare enrollee receives a unit, complicating the reimbursement process.
Revenue Decline
Ekso Bionics reported a 2% year-over-year decline in total revenue for 2024, mainly due to lower enterprise sales.

EKSO BIONICS (EKSO) vs. SPDR S&P 500 ETF (SPY)

EKSO BIONICS Business Overview & Revenue Model

Company DescriptionEkso Bionics (EKSO) is a pioneering company in the field of wearable robotics and exoskeleton technology. Founded in 2005 and headquartered in Richmond, California, Ekso Bionics develops and manufactures powered exoskeletons that enhance human strength, endurance, and mobility. The company's core products are designed for medical and industrial applications, helping individuals with lower extremity weakness or paralysis to stand and walk, as well as aiding workers in performing physically demanding tasks more safely and efficiently.
How the Company Makes MoneyEkso Bionics generates revenue through the sale and leasing of its exoskeleton products, primarily targeting the healthcare and industrial sectors. In healthcare, Ekso Bionics markets its exoskeletons to rehabilitation centers and hospitals, where they are used as therapeutic tools to aid in the recovery of patients with spinal cord injuries, strokes, and neurological conditions. The company also offers training and support services to ensure effective product use, contributing to its revenue streams. In the industrial sector, Ekso Bionics sells or leases its exoskeletons to companies looking to improve worker safety and productivity by reducing physical strain and the risk of injuries. Additionally, the company may engage in partnerships or collaborations with research institutions and organizations to further develop and expand its technology, potentially creating additional revenue opportunities.

EKSO BIONICS Earnings Call Summary

Earnings Call Date:May 05, 2025
(Q1-2025)
|
% Change Since: -51.61%|
Next Earnings Date:Jul 24, 2025
Earnings Call Sentiment Neutral
The earnings call presented a mixed outlook. While there were significant achievements such as improved gross margin, reduced net loss, and growth in the personal health segment supported by strategic partnerships, these were somewhat offset by a decline in overall revenue and challenges in the enterprise health segment due to economic uncertainties.
Q1-2025 Updates
Positive Updates
Improved Gross Margin
The company reported a gross margin of approximately 54% for Q1 2025, up from 52% in the same period of 2024, driven by cost savings in supply chain and reduction in service costs.
Reduced Net Loss
Net loss for Q1 2025 was $2.9 million, significantly lower than the net loss of $3.4 million in Q1 2024.
Increased Cash and Restricted Cash
The company reported cash and restricted cash of $8.1 million as of March 31, 2025, up from $6.5 million at the end of 2024.
Personal Health Segment Growth
The CMS pricing determination for the Indigo Personal exoskeleton has created significant opportunities. A pipeline of more than 35 Medicare beneficiaries was developed, a 37% increase from the previous quarter.
New Strategic Partnerships
The company engaged PRIA Healthcare for market access services and announced partnerships with Bionic P&O and National Seating & Mobility to expand distribution for Indigo Personal.
Negative Updates
Decline in Revenue
Revenue for Q1 2025 was $3.4 million, a decrease from $3.8 million in Q1 2024, primarily due to capital budget impacts affecting the Enterprise Health product.
Softness in Enterprise Health Segment
The legacy enterprise business saw some softness due to customers' capital budgets being impacted by macroeconomic uncertainties.
Company Guidance
During the first quarter of 2025, Ekso Bionics reported a revenue of $3.4 million, down from $3.8 million in the same period of 2024, attributed to capital budget constraints impacting their EksoNR Enterprise Health product. Gross profit stood at $1.8 million, marking a gross margin of 54%, slightly up from 52% in 2024. Operating expenses were stable at $5.3 million compared to $5.2 million in the previous year. The company reduced its net loss to $2.9 million, or $0.12 per share, from $3.4 million, or $0.20 per share, in 2024. Ekso Bionics also improved its cash position, with $8.1 million in cash and restricted cash as of March 31, 2025, up from $6.5 million at the end of 2024. The company's focus is on leveraging new partnerships with distributors like National Seating & Mobility and Bionic P&O to expand the reach of its Ekso Indego Personal exoskeleton, aiming to increase its contribution to revenue while navigating economic uncertainties affecting capital budget allocations in the Enterprise Health segment.

EKSO BIONICS Financial Statement Overview

Summary
EKSO BIONICS faces ongoing financial challenges characterized by negative profitability and cash flow metrics. While there are signs of improvement in operational efficiency and cash flow management, the company needs to address its persistent losses and reliance on external financing. The moderate leverage and stable equity position offer some stability, yet achieving consistent revenue growth and profitability remains crucial for long-term sustainability.
Income Statement
55
Neutral
EKSO BIONICS has shown a volatile revenue trajectory with a slight revenue decline of 1.94% from 2023 to 2024. The gross profit margin improved to 53.06% in 2024 from 49.68% in 2023, indicating efficiency in controlling direct costs. However, the company continues to face challenges with profitability, as evidenced by a negative net profit margin of -63.21% in 2024, despite improving from -83.17% in 2023. The EBIT and EBITDA margins remain negative, reflecting ongoing operational challenges.
Balance Sheet
50
Neutral
EKSO BIONICS' balance sheet reflects a stable equity position with an equity ratio of 47.68% as of 2024. The debt-to-equity ratio stands at 0.47, indicating moderate leverage, which has slightly decreased from 0.57 in 2023. However, the return on equity remains negative at -89.17% due to persistent net losses, highlighting a challenging environment for shareholder returns.
Cash Flow
45
Neutral
The cash flow statement reveals a negative free cash flow for 2024, although it improved by 19.46% compared to 2023. The operating cash flow to net income ratio is 0.87, suggesting that operational cash generation is not sufficient to cover net losses. The company is heavily reliant on financing activities to support cash flow needs.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue17.54M17.93M18.28M12.91M11.25M8.88M
Gross Profit9.37M9.51M9.08M6.21M6.75M5.07M
EBITDA-9.93M-9.45M-13.20M-14.04M-9.09M-15.07M
Net Income-10.79M-11.33M-15.20M-14.60M-8.43M-16.95M
Balance Sheet
Total Assets27.31M26.65M28.92M40.90M49.17M20.60M
Cash, Cash Equivalents and Short-Term Investments0.006.49M8.64M20.52M40.41M12.86M
Total Debt5.62M5.98M7.17M7.50M2.22M3.86M
Total Liabilities14.62M13.95M16.31M15.46M11.95M16.16M
Stockholders Equity12.69M12.71M12.61M25.44M37.22M4.43M
Cash Flow
Free Cash Flow-8.37M-9.88M-12.21M-14.88M-11.21M-8.76M
Operating Cash Flow-8.35M-9.85M-12.05M-14.69M-11.16M-8.76M
Investing Cash Flow-39.00K-37.00K-157.00K-5.17M-59.00K0.00
Financing Cash Flow7.64M7.77M348.00K176.00K38.71M10.70M

EKSO BIONICS Technical Analysis

Technical Analysis Sentiment
Negative
Last Price3.46
Price Trends
50DMA
4.80
Negative
100DMA
5.78
Negative
200DMA
8.93
Negative
Market Momentum
MACD
-0.37
Negative
RSI
42.06
Neutral
STOCH
53.96
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EKSO, the sentiment is Negative. The current price of 3.46 is below the 20-day moving average (MA) of 3.54, below the 50-day MA of 4.80, and below the 200-day MA of 8.93, indicating a bearish trend. The MACD of -0.37 indicates Negative momentum. The RSI at 42.06 is Neutral, neither overbought nor oversold. The STOCH value of 53.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for EKSO.

EKSO BIONICS Risk Analysis

EKSO BIONICS disclosed 22 risk factors in its most recent earnings report. EKSO BIONICS reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

EKSO BIONICS Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
52
Neutral
$7.45B0.27-61.87%2.30%16.62%1.04%
49
Neutral
$64.44M-354.27%-14.55%34.87%
48
Neutral
$19.59M-138.80%-14.41%-549.88%
46
Neutral
$7.85M-80.71%-2.06%49.73%
44
Neutral
$53.36M-88.36%-9.13%30.04%
44
Neutral
$30.23M-239.87%61.97%-6.89%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
EKSO
EKSO BIONICS
3.46
-12.74
-78.64%
HBIO
Harvard Bioscience
0.46
-2.32
-83.45%
MLSS
Milestone Scientific
0.66
-0.05
-7.04%
AKYA
Akoya Biosciences
1.29
-0.77
-37.38%
FEMY
Femasys
0.92
-0.18
-16.36%

EKSO BIONICS Corporate Events

Delistings and Listing ChangesShareholder MeetingsStock Split
Ekso Bionics Announces Reverse Stock Split Approval
Neutral
May 21, 2025

On May 16, 2025, Ekso Bionics’ stockholders approved a reverse stock split at a 1-for-15 ratio, which will take effect on June 2, 2025. The split aims to increase the company’s stock price to meet Nasdaq’s minimum bid requirement, reducing the number of outstanding shares from approximately 35.5 million to 2.4 million.

The most recent analyst rating on (EKSO) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on EKSO BIONICS stock, see the EKSO Stock Forecast page.

Delistings and Listing ChangesShareholder MeetingsStock Split
Ekso Bionics Approves Reverse Stock Split Plan
Neutral
May 20, 2025

On May 16, 2025, Ekso Bionics held its Annual Meeting of Stockholders where several key proposals were approved, including a reverse stock split at a ratio of 1-for-15, effective May 27, 2025. This move is primarily intended to increase the per-share trading price and help the company regain compliance with Nasdaq’s minimum bid price requirement, ensuring its continued listing on the Nasdaq Capital Market.

The most recent analyst rating on (EKSO) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on EKSO BIONICS stock, see the EKSO Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 27, 2025